NEW DELHI — The Serum Institute of India said on Tuesday it plans this year to produce up to 60 million doses of a potential vaccine against the new coronavirus that is under clinical trial in Britain.
Serum, the world’s largest maker of vaccines by volume, is mass-producing the vaccine candidate developed by the University of Oxford, which started testing it on humans last week, and is a leader in the global race to develop an antidote to the novel coronavirus.
Some 3.05 million people have been reported to be infected globally and 211,376 have died from COVID-19, the respiratory disease caused by the coronavirus, according to a Reuters tally.
While the Oxford vaccine, called "ChAdOx1 nCoV-19", is yet to be proven to work against COVID-19, Serum decided to start manufacturing it as it had shown success in animal trials and had progressed to tests on humans, Serum Chief Executive Adar Poonawalla said.
ByReuters
April 28, 2020